73 Results for "

cdk8

" in MedChemExpress (MCE) Product Catalog:
Products (73)

73 Results for "cdk8" in MCE Product Catalog:

  • Isoforms Recommended:
  • Targets Recommended:
  • Recombinant Proteins Recommended:
24
24 Publications Verification
Cat. No.: HY-N0400
CAS No.: 632-85-9
Wogonin is a naturally occurring mono-flavonoid, can inhibit the activity of CDK8 and Wnt, and exhibits anti-inflammatory and anti-tumor effects.
9
9 Cited Publications
Cat. No.: HY-15681
CAS No.: 1366002-50-7
Purity:  99.79%
Target:  

CDK

Research Areas:  

Cancer

Senexin A is an inhibitor of CDK8/19 (IC50: 280 nM, CDK8) and an inhibitor downstream of p21 transcription. It only inhibits p21-induced transcription but does not inhibit other biological effects of p21. Senexin A inhibits CMV-GFP induction as well as the p21 stimulatory activity of the consensus NF-κB-dependent promoters .
8
8 Cited Publications
Cat. No.: HY-111388A
CAS No.: 2443816-41-7
Purity:  99.29%
Synonyms: SEL120-34A monohydrochloride
Target:  

CDK

Research Areas:  

Cancer

SEL120-34A monohydrochloride is an ATP-competitive and selective CDK8 inhibitor, inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50s of 4.4 nM and 10.4 nM, respectively, with a Kd of 3 nM for CDK8. SEL120-34A monohydrochloride weakly inhibits CDK9 (calculated IC50=1070 nM), but shows no obvious activity against CDK1, 2, 4, 6, 5, 7. SEL120-34A monohydrochloride inhibits phosphorylation of STAT1 S727 and STAT5 S726 . Has anti-tumor activity .
8
8 Cited Publications
Cat. No.: HY-111388B
CAS No.: 1609452-30-3
Purity:  99.82%
Synonyms: SEL120-34A hydrochloride
Target:  

CDK

Research Areas:  

Cancer

SEL120-34A hydrochloride is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity.
8
8 Cited Publications
Cat. No.: HY-111388
CAS No.: 1609522-33-9
Target:  

CDK

Research Areas:  

Cancer

SEL120-34A is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity.
7
7 Cited Publications
Cat. No.: HY-120350
CAS No.: 2163056-91-3
Purity:  99.84%
Target:  

CDK

Research Areas:  

Cancer

BI-1347 is an orally active, selective and potent CDK8 inhibitor (IC50=1.1 nM). BI-1347 shows anti-tumoral activity .
6
6 Cited Publications
Cat. No.: HY-126675A
CAS No.: 2241300-51-4
Purity:  99.94%
Research Areas:  

Inflammation/Immunology

AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4 + T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects .
6
6 Cited Publications
Cat. No.: HY-126675
CAS No.: 2241300-50-3
Purity:  99.68%
Research Areas:  

Inflammation/Immunology

AS2863619 free base is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 free base targets Stat5a-CDK8/19 to promote the differentiation of CD4 + T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 free base also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 free base exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 free base can be applied to research in related fields such as periodontitis-induced bone defects .
4
4 Cited Publications
Cat. No.: HY-19984
CAS No.: 1607837-31-9
Target:  

CDK

Research Areas:  

Cancer

CCT-251921 is a potent, selective, and orally bioavailable CDK8 inhibitor with an IC50 of 2.3 nM.
4
4 Cited Publications
Cat. No.: HY-12293
CAS No.: 1619903-54-6
Purity:  99.92%
Target:  

CDK Apoptosis

Research Areas:  

Cancer

LY2857785 is a type I reversible and competitive ATP kinase inhibitor against CDK9 (IC50 11 nM) and other transcription kinases CDK8 (IC50 16 nM), and CDK7 (IC50 246 nM).
3
3 Cited Publications
Cat. No.: HY-101611
CAS No.: 1883423-59-3
Purity:  99.52%
Target:  

CDK

Research Areas:  

Cancer

MSC2530818 is a potent, selective and orally available CDK8 inhibitor with an IC50 of 2.6 nM for CDK8.
3
3 Cited Publications
Cat. No.: HY-12681
CAS No.: 1661839-45-7
Purity:  99.39%
Target:  

Wnt

Research Areas:  

Cancer

CCT251545 is an orally bioavailable and potent inhibitor of WNT signaling with an IC50 of 5 nM in 7dF3 cells . CCT251545 is a selective chemical probe for exploring the role of CDK8 and CDK19 in human disease .
2
2 Cited Publications
Cat. No.: HY-101800
CAS No.: 1449228-40-3
Purity:  99.09%
Synonyms: SNX2-1-165; BCD-115
Target:  

CDK

Research Areas:  

Cancer

Senexin B (SNX2-1-165; BCD-115) is a potent, highly water-soluble and bioavailable CDK8/19 inhibitor, with Kds of 140 nM for CDK8 and 80 nM for CDK19.
2
2 Cited Publications
Cat. No.: HY-122586
CAS No.: 642008-81-9
Purity:  99.56%
Target:  

CDK Interleukin Related

Research Areas:  

Inflammation/Immunology

BRD6989, an analog of the natural product cortistatin A (dCA), inhibits CDK8 and upregulates IL-10. BRD6989 selectively binds a complex of CDK8 with an IC50 of ~200 nM. BRD6989 inhibits the kinase activity of recombinant CDK8 or CDK19 complexes .
2
2 Cited Publications
Cat. No.: HY-111518
CAS No.: 2209085-22-1
Purity:  99.82%
Target:  

PROTACs CDK

Research Areas:  

Cancer

JH-XI-10-02 is a PROTAC connected by ligands for Cereblon and CDK. JH-XI-10-02 is a highly potent and selective PROTAC CDK8 degrader, with an IC50 of 159 nM. JH-XI-10-02 causes proteasomal degradation, does not affect CDK8 mRNA levels. JH-XI-10-02 shows no effect on CDK19 .
1
1 Cited Publications
Cat. No.: HY-139875
CAS No.: 2648453-53-4
Purity:  98.87%
Target:  

CDK

Research Areas:  

Cancer

JH-XVI-178 is a highly efficient and selective CDK8/19 inhibitor, with IC50 values of 1 and 2 nM for CDK8 and CDK19, respectively. JH-XVI-178 has a low clearance rate and moderate oral pharmacokinetic properties .
1
1 Cited Publications
Cat. No.: HY-N9561
CAS No.: 155179-21-8
Vanicoside B is a phenylpropanoyl sucrose derivative, can be isolated from the herb Persicaria dissitiflora. Vanicoside B targets cyclin-dependent kinase 8 (CDK8) and exhibits anti-tumor activity. The potential mechanism is Vanicoside B blocks CDK8-mediated signaling pathways and decreases the expression of epithelial-mesenchymal transition proteins, so that it leads to cell cycle arrest and apoptosis .
1
1 Cited Publications
Cat. No.: HY-111465
CAS No.: 1613638-82-6
Purity:  99.39%
Target:  

CDK

Research Areas:  

Cancer

CDK8-IN-4 is an inhibitor of CDK8 extracted from patent WO2014090692A1, compound example 16, with an IC50 of 0.2 nM.
1
1 Cited Publications
Cat. No.: HY-P701373
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: cdk8; CCNC; MED12; Cyclin-dependent kinase 8; Cell division protein kinase 8; Mediator complex subunit cdk8; Mediator of RNA polymerase II transcription subunit cdk8; Protein kinase K35; Cyclin-C; SRB11 homolog; hSRB11; Mediator of RNA polymerase II transcription subunit 12; Activator-recruited cofactor 240 kDa component; ARC240; CAG repeat protein 45; Mediator complex subunit 12; OPA-containing protein; Thyroid hormone receptor-associated protein complex 230 kDa component; Trap230; Trinucleotide repeat-containing gene 11 protein
Species:  
Source:  
Cat. No.: HY-148561
CAS No.: 2613307-67-6
Purity:  99.74%
Target:  

CDK GSK-3 PKC

Research Areas:  

Cancer

CDK8-IN-12 is an orally active, potent CDK8 inhibitor with a Ki of 14 nM. CDK8-IN-12 has off-target kinase inhibition on GSK-3α, GSK-3β, PCK-θ with Kis of 13 nM, 4 nM, 109 nM, respectively. CDK8-IN-12 shows potent anti-proliferative effects selectively on MV4-11 cell. CDK8-IN-12 is an anti-cancer agent .